Welcome to our dedicated page for KEWAUNEE SCIENTIFIC /DE/ SEC filings (Ticker: KEQU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KEWAUNEE SCIENTIFIC /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KEWAUNEE SCIENTIFIC /DE/'s regulatory disclosures and financial reporting.
Kewaunee Scientific Corporation (KEQU) reported weaker first-quarter FY2027 results for the three months ended July 31, 2026, as net sales declined to $66.3 million from $71.1 million a year earlier, reflecting softer demand in the domestic laboratory construction market and India.
Net earnings attributable to Kewaunee fell to $1.7 million from $3.1 million, and diluted EPS decreased to $0.58 from $1.04, driven mainly by lower sales and a higher effective tax rate, partly offset by slightly improved gross margin of 29.6% versus 29.4% and reduced interest expense.
Order backlog was $169.0 million at July 31, 2026, down from $205.0 million a year earlier but modestly above $165.9 million at April 30, 2026. Operating cash flow was $2.0 million versus $5.8 million in the prior-year quarter, while term loan balances declined to $18.8 million and cash, cash equivalents and restricted cash totaled $10.3 million. The company repurchased 14,290 shares under its ongoing buyback program and ended the quarter with 2,895,347 shares outstanding and full $20.0 million availability on its revolving credit facility.
Kewaunee Scientific Corporation (KEQU) reported softer results for the first quarter of fiscal 2027 ended July 31, 2026, with net sales of $66.3 million, down 6.7% from $71.1 million a year earlier. Net earnings attributable to the company were $1.7 million versus $3.1 million, and diluted EPS declined to $0.58 from $1.04. Consolidated EBITDA fell to $4.5 million from $6.3 million.
The Lab Products Group segment delivered sales of $50.9 million (down 6.4%), with segment net earnings of $3.9 million and EBITDA of $6.6 million, as cost controls and efficiencies helped offset lower life sciences volumes. International segment sales were $15.5 million (down 7.8%), but segment net earnings rose 23.5% to $0.8 million and segment EBITDA increased 13.9% to $1.2 million on a higher-margin project mix.
Order backlog increased sequentially to $169.0 million at July 31, 2026 from $165.9 million at April 30, 2026, though it remained below $205.0 million a year earlier. Long-term debt, excluding the sale-leaseback financing obligation, declined to $13.8 million from $15.1 million at April 30, 2026, and the debt-to-equity ratio improved slightly. Corporate results were pressured by non-recurring compensation expense from settling specific long-term incentive awards in cash rather than shares.
KEWAUNEE SCIENTIFIC CORP (KEQU) reported results of its August 26, 2026 Annual Meeting of Shareholders. Shareholders re-elected Class I directors Thomas D. Hull III, David S. Rhind, and John D. Russell to three-year terms, each receiving over 1.46 million votes in favor.
Shareholders also ratified the appointment of Forvis Mazars, LLP as independent registered public accounting firm for fiscal 2027, with 2,516,379 votes for and very few opposing or abstaining votes. On an advisory "say-on-pay" basis, compensation of named executive officers for the year ended April 30, 2026 was approved, receiving 1,586,496 votes for, compared with 36,616 against.
Kewaunee Scientific Corporation (KEQU) used its annual meeting investor presentation to highlight continued growth and balance-sheet strengthening for fiscal year 2026, ended April 30, 2026. Revenue reached $282.0 million, extending a multi‑year growth trajectory and representing nearly a 14% CAGR since fiscal 2021.
EBITDA increased to $22.4 million, growing at nearly a 157% CAGR over five years, while consolidated order backlog was $165.9 million, down from $214.6 million as large international projects were completed. Long‑term debt was reduced by about $20 million, improving the debt‑to‑equity ratio to 0.61‑to‑1.0 from 0.99‑to‑1.0.
The renamed Lab Products Group (formerly Domestic) delivered $214.9 million in sales, up 19.8%, driven by a full year of NuAire results, with EBITDA of $25.1 million. International sales rose to $67.1 million and EBITDA to $5.9 million, supported by delivery of previously delayed projects in India. Kewaunee also emphasized investments in SOX 404(b) readiness, governance, systems, and international expansion to support further organic and acquisition‑driven growth.
KEWAUNEE SCIENTIFIC CORP (KEQU) announced that it plans to release its first quarter fiscal year 2027 financial results on Wednesday, September 9, 2026, after the close of trading. The results will be made available on the company’s website.
Kewaunee Scientific also reiterates its role as a global provider of laboratory, healthcare, and technical furniture, with manufacturing operations in North Carolina, Minnesota, and India, and sales or warehouse partnerships across the United States, Europe, the Middle East, and Asia. The announcement includes standard forward-looking statement cautions referencing risk factors in its Form 10-K for the year ended April 30, 2026.
Kewaunee Scientific Corporation will hold its 2026 Annual Meeting virtually on August 26, 2026 at 11:00 a.m. Eastern Time. Stockholders will vote on electing three Class I directors to serve until the 2029 meeting, ratifying Forvis Mazars, LLP as independent auditor for fiscal 2027, and approving on an advisory basis the compensation of named executive officers.
The Board is majority independent, with separate Chair and CEO roles and active Audit, Compensation, Financial/Planning, and Nominating and Corporate Governance Committees. Non-employee directors received a $120,000 annual retainer in fiscal 2026, generally half in cash and half in fully vested stock, plus additional cash fees for committee and Board leadership roles.
Executive pay combines base salary, annual incentives tied mainly to EBITDA and non-financial objectives, and long-term incentives in time- and performance-based RSUs under the 2023 Omnibus Incentive Plan. For fiscal 2026, CEO Thomas D. Hull III had base salary of $526,190 and total compensation of $1,965,495, including a $394,967 cash bonus. The company reports net income of $9.618 million in 2026 and a Company Total Shareholder Return value of $227.75 on an initial $100 investment over the three-year measurement period.
Kewaunee Scientific senior vice president of People & Culture Elizabeth D. Phillips reported compensation-related stock transactions. On June 30, 2026, she exercised restricted stock units, acquiring 6,656 shares of common stock. Of these, 793 shares were withheld at $36.25 per share to cover tax obligations.
Footnotes state that performance-based RSUs vested at 150% of target, with RSUs otherwise entitling her to 4,995 shares settled in cash through a disposition to the issuer at $36.25 per share, while 475 service-based RSUs delivered 475 shares. After these transactions, she directly holds 9,116 shares of common stock.
Kewaunee Scientific senior vice president of IT & Engineering Mandar Ranade reported several equity compensation transactions dated June 30, 2026. He exercised awards to acquire 7,227 shares of common stock at a stated price of $0.0000 per share, tied to vested restricted stock units. Footnotes explain that 4,159 shares were delivered upon settlement of service- and performance-based RSUs, while an additional portion of performance-based RSUs was settled in cash in lieu of 1,800 shares. To cover obligations, 1,877 shares were disposed of at $36.25 per share as a tax-withholding transaction and 1,800 shares were returned to the company at the same price as a disposition to the issuer. After these moves, Ranade directly holds 16,215 shares of common stock.
Kewaunee Scientific senior vice president of sales and marketing development Ryan S. Noble reported several equity compensation transactions in the company’s common stock. On June 30, 2026, he exercised awards to acquire 7,206 shares of common stock, primarily from vested restricted stock units. To cover obligations tied to this settlement, 1,809 shares were used in a tax-withholding disposition at $36.25 per share, and 3,000 shares were delivered back to the issuer as a disposition to the company at the same price. After these transactions, Noble directly held 16,240 shares of common stock. He also continued to hold unvested or unsettled restricted stock units from more recent grants, including FY25 and FY26 awards that are subject to service-based and performance-based vesting conditions.